Following an initial explosion of excitement across the allogeneic space, challenges around safety and long-term persistence and durability has highlighted the need for the industry to determine key contributing factors affecting the product performance – one of which is the starting quality of the cell source material being utilized.

As the allogeneic space continues to ramp up clinical development, drug developers are realizing the need to plan ahead in donor management and develop robust processes to support scale up.

From our research, leading experts in the field have mentioned they need help from service providers and require meaningful partnerships to aid with characterization testing, donor recruitment, retention, management and more!

The 2nd Donor Selection and Cell Source Summit provided the unique opportunity to position your trusted expertise to those at the forefront of building out their donor requirements for allogeneic cell therapy pipelines.